MedPath

Unloading Induced Effects on Local Glucose Uptake Into m. Soleus

Not Applicable
Completed
Conditions
Glucose Metabolism Disorders
Local Glucose Uptake
Interventions
Device: HEPHAISTOS unloading orthotic device
Dietary Supplement: lupin protein
Other: Neuromuscular electrical stimulation
Registration Number
NCT02698878
Lead Sponsor
DLR German Aerospace Center
Brief Summary

The present study aimed to investigate whether a daily intake of lupin protein and a neuromuscular electrical stimulation training twice a day can improve local glucose uptake into m. soleus during a 60 day unloading phase with a special unloading device, the HEPHAISTOS orthosis (HEP).

Detailed Description

The 60 day unloading intervention with the HEPHAISTOS unloading device had the following key objectives:

primary hypothesis:

* Assesment and evaluation of insulin sensitivity and local glucose uptake in the unloaded m. soleus and whether it can be improved by dietary supplementation of lupin seeds and neuromuscular electrical stimulation.

secondary hypotheses:

* Assesment and evaluation of unloading-induced reductions in muscle mass and whether they can be mitigated by dietary supplementation of lupin seed and neuromuscular electrical stimulation.

* Assesment and evaluation of whole-body glycemic effects of the interventions.

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
13
Inclusion Criteria
  • Male volunteers
  • Age: between 20 and 45 years
  • Body mass index (BMI): 20 -26 kg/m2
  • Agreement and signed consent before the study
Exclusion Criteria
  • Smoker
  • Competitive Athletes
  • Diabetes mellitus
  • Rheumatic disease
  • Muscle or joint disease
  • Bone fractures in the period up to one year before study start
  • Herniated disc
  • Flatfeet (pes planus)
  • Allergy to nuts or legume
  • Vascular diseases
  • Epilepsy
  • Severe hyperlipidemia
  • Anemia (< Hb standard values; standard values healthy men: 13.5 -17.5 g/dl) *
  • Increased thrombosis risk *
  • Kidney disorder: deviations from normal values for creatinine in plasma. (Normal value: Creatinine < 1.20 mg/dl)*
  • Lesions of the cruciate ligaments, or orthopedic surgery in the past 10 years on the side of the Hephaistos orthosis
  • Achilles tendon injury, or rupture in the past 10 years on the side of the orthosis
  • hyper-/hypocalcaemia (abnormal levels of calcium in the blood, normal level: 2.15 - 2.64 mmol/l)
  • Intake of anti-inflammatory drugs during the study
  • Abuse of drugs or alcohol (> than 20-30g alcohol/day)
  • Participation in another clinical study within the last 2 months before the start of this study
  • Increased bleeding tendency (hemophilia, regular use of anticoagulants)
  • History of intolerance to local anesthetics
  • Imprisoned during study
  • Any other condition classed as unsuitable for study participation by the medical executive director
  • prior convictions (objectionable criminal record)

Additional Exclusion Criteria for MRI

  • Metal implants or other osteosynthesis material
  • Pacemaker
  • Claustrophobia

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Intervention GroupNeuromuscular electrical stimulationIntervention group consisting of seven healthy mal subjects, wearing the HEPHAISTOS orthosis for lower leg unloading (60 days), plus receiving lupin protein every day and performing a neuromuscular electrical stimulation training twice a day.
Control GroupHEPHAISTOS unloading orthotic deviceControl Group consisting of six healthy male subjects wearing only the HEPHAISTOS ORTHOSIS for lower leg unloading (60 days).
Intervention Grouplupin proteinIntervention group consisting of seven healthy mal subjects, wearing the HEPHAISTOS orthosis for lower leg unloading (60 days), plus receiving lupin protein every day and performing a neuromuscular electrical stimulation training twice a day.
Intervention GroupHEPHAISTOS unloading orthotic deviceIntervention group consisting of seven healthy mal subjects, wearing the HEPHAISTOS orthosis for lower leg unloading (60 days), plus receiving lupin protein every day and performing a neuromuscular electrical stimulation training twice a day.
Primary Outcome Measures
NameTimeMethod
Changes in Local Glucose Uptake into m. soleusBaseline to day 59 of the intervention phase

Biopsies were taken from m. soleus

Changes in Local Glucose Metabolism in m. soleusBaseline to day 60 of the intervention phase

Microdialysis was performed in m. soleus

Secondary Outcome Measures
NameTimeMethod
Changes in Muscle Function (jump performance)Baseline to day 58 of the intervention phase

A jump test was performed

Blood Glucose (changes in the whole body glucose metabolism)Baseline and day 2 & 1 before the intervention phase, day 4, 14, 28, 42 & 60 of the intervention phase and day 2 & 14 after the intervention phase
Changes in Muscle Function (MVC)Baseline to day 58 of the intervention phase

Maximal voluntary contractions (MVC) - isometric and isokinetic - were performed

ComplianceDuring 60 days of intervention

Electronic wearing time devices from Orthotimer were used to assess compliance of the subjects.

Blood C-Peptide (changes in the whole body glucose metabolism)Baseline and day 2 & 1 before the intervention phase, day 4, 14, 28, 42 & 60 of the intervention phase and day 2 & 14 after the intervention phase
Blood HbA1c (changes in the whole body glucose metabolism)Baseline and day 2 & 1 before the intervention phase, day 4, 14, 28, 42 & 60 of the intervention phase and day 2 & 14 after the intervention phase
Blood Fructosamine (changes in the whole body glucose metabolism)Baseline and day 2 & 1 before the intervention phase, day 4, 14, 28, 42 & 60 of the intervention phase and day 2 & 14 after the intervention phase
Changes in Muscle VolumeBaseline to day 58 of the intervention phase

Muscle volume measured by magnetic resonance imaging (MRI)

Insulin Sensitivity (changes in the whole body glucose metabolism)Baseline and day 60 of the intervention phase

Whole body insulin sensitivity assessed by hyperinsulinemic euglycemic clamp

MovementDuring 60 days of intervention and during 14 days of the recovery phase (post intervention phase)

Accelerometers were used to assess movement of the subjects.

© Copyright 2025. All Rights Reserved by MedPath